Progenics Pharmaceuticals Inc (PGNX): Paul J Maddon , director of Progenics Pharmaceuticals Inc purchased 5,000 shares on Dec 1, 2010. The Insider buying transaction was reported by the company on Apr 22, 2016 to the Securities and Exchange Commission. The shares were purchased at $4.90 per share for a total value of $24,500.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 15, 2015, Robert J Israel (Executive Vice President, Medi) sold 2,000 shares at $6.83 per share price.
Progenics Pharmaceuticals: On Wednesday, Apr 20, 2016 heightened volatility was witnessed in Progenics Pharmaceuticals which led to swings in the share price. The shares opened for trading at $5.08 and hit $5.29 on the upside , eventually ending the session at $5.23, with a gain of 2.75% or 0.14 points. The heightened volatility saw the trading volume jump to 7,62,890 shares. The 52-week high of the share price is $11.15 and the company has a market cap of $366 M . The 52-week low of the share price is at $3.61.
Progenics Pharmaceuticals Inc.is engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC 1404 (trofolastat) and Azedra. PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a radiotherapeutic product candidate in development as a treatment for pheochromocytoma a rare tumor found in the adrenal glands and related paraganglioma tumors occurring in other tissues. The Company also commercializes Relistor a cure for opioid-induced constipation (OIC).